Jaguar Health Inc
JAGX.OQ- Latest Trade
- trading higher0.31USD
- Change
- 0.01
- % Change
4.83%Positive
- Day Range
- 0.29 - 0.31
- 52-Week Range
- 0.27 - 5.13
As of Jul 4 2022. Values delayed up to 15 minutes
- Previous Close
- 0.29
- Open
- 0.29
- Volume
- 104,751.00
- 3 Month Average Trading Volume
- 38.02
- Shares Out (Mil)
- 79.98
- Market Cap
- 24.35
- Forward P/E
- -0.33
- Dividend Yield
- -99,999.99
Key Statistics
1.5 mean rating - 2 analysts
- P/E Excl. Extra Items (TTM)
- -99,999.99
- Price To Sales (TTM)
- 4.26
- Price To Book (Quarterly)
- 3.03
- Price To Cash Flow (Per Share TTM)
- -99,999.99
- Total Debt/Total Equity (Quarterly)
- 393.70
- Long Term Debt/Equity (Quarterly)
- 308.05
- Return On Investment (TTM)
- -130.76
- Return On Equity (TTM)
- -96.62
2021 (millions USD)
About Jaguar Health Inc
Company Information
Jaguar Health, Inc. is a commercial stage pharmaceutical company. The Company is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea. The Company operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. Its Canalevia-CA1 is used for chemotherapy-induced diarrhea in dogs. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. Its wholly owned subsidiary is Napo Pharmaceuticals, Inc.
Address
200 PINE STREET SUITE 400SAN FRANCISCO, CA
94104
United States
Industry
Biotechnology & Drugs
Executive Leadership
- James J. Bochnowski
- Independent Chairman of the Board
- Lisa A. Conte
- President, Chief Executive Officer, Director
- Carol R. Lizak
- Chief Financial Officer
- Pravin R. Chaturvedi
- Chief Scientific Officer
- Jonathan S. Wolin
- Chief of Staff, General Counsel, Chief Compliance Officer
- Ian Wendt
- Chief Commercial Officer
- Steven R. King
- Chief of Sustainable Supply - Ethnobotanical Research and Intellectual Property, Secretary
- Gregory J. Divis
- Independent Director
- John J. Micek
- Independent Director
- Jonathan B. Siegel
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,805.20 | 0.35%Positive |
| Copper | 674.55 | 0.66%Negative |
| Brent Crude Oil | 113.83 | 1.97%Positive |
| CBOT Soybeans | 1,626.00 | -- |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,825.33 | 1.06%Positive |
| Euro STOXX 50 | 3,452.42 | 0.12%Positive |
| FTSE 100 | 7,232.65 | 0.89%Positive |
| Nikkei 225 | 26,153.81 | -- |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes